Current understanding of human megakaryocytic-erythroid progenitors and their fate determinants.

Autor:	Kwon N; Department of Cell Biology.; Yale Stem Cell Center., Thompson EN; Department of Cell Biology.; Yale Stem Cell Center., Mayday MY; Yale Stem Cell Center.; Department of Pathology., Scanlon V; Yale Stem Cell Center.; Department of Laboratory Medicine, Yale School of Medicine, New Haven, Connecticut, USA., Lu YC; Yale Stem Cell Center.; Department of Laboratory Medicine, Yale School of Medicine, New Haven, Connecticut, USA., Krause DS; Department of Cell Biology.; Yale Stem Cell Center.; Department of Pathology.; Department of Laboratory Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
Jazyk:	angličtina
Zdroj:	Current opinion in hematology [Curr Opin Hematol] 2021 Jan; Vol. 28 (1), pp. 28-35.
DOI:	10.1097/MOH.0000000000000625
Abstrakt:	Purpose of Review: This review focuses on our current understanding of fate decisions in bipotent megakaryocyte-erythroid progenitors (MEPs). Although extensive research has been carried out over decades, our understanding of how MEP commit to the erythroid versus megakaryocyte fate remains unclear. Recent Findings: We discuss the isolation of primary human MEP, and focus on gene expression patterns, epigenetics, transcription factors and extrinsic factors that have been implicated in MEP fate determination. We conclude with an overview of the open debates in the field of MEP biology. Summary: Understanding MEP fate is important because defects in megakaryocyte and erythrocyte development lead to disease states such as anaemia, thrombocytopenia and leukaemia. MEP also represent a model system for studying fundamental principles underlying cell fate decisions of bipotent and pluripotent progenitors, such that discoveries in MEP are broadly applicable to stem/progenitor cell biology.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu